This course requires successful completion of a post-activity assessment. A minimum score of 70% is required to complete this 10 question assessment. Select the best answer for each of the questions. All questions must be answered in order to score the post-activity assessment.
0 of 10 questions completed
You have already completed the assessment before. Hence you can not start it again.
Assessment is loading...
You must sign in or sign up to start the assessment.
You must first complete the following:
0 of 10 questions answered correctly
Time has elapsed
You have reached 0 of 0 point(s), (0)
Earned Point(s): 0 of 0, (0)
0 Essay(s) Pending (Possible Point(s): 0)
It is estimated that 95% of patients with smoldering multiple myeloma who have ≥____% plasma cells in the bone marrow will progress to active multiple myeloma within 2 years
Patients with smoldering multiple myeloma who have an ultra-high risk (≥80% chance of progression to active disease within 2 years) as outlined in the updated IMWG diagnostic criteria (2014), are now being treated as having active myeloma.
Aside from multiagent chemotherapy, which other myeloma therapy has the highest risk for venous thromboembolism?
Which of the following statements about myeloma-associated infections is NOT true?
Approaches for preventing treatment-related peripheral neuropathy may include:
Which of the following statements about post-transplant relapsed myeloma treatment is NOT true?
In 3 major clinical trials, daratumumab-containing triplet regimens demonstrated a superior overall response rate and a consistent progression-free survival rate across subgroups in patients with relapsed and/or refractory myeloma, compared with doublet therapy alone (without daratumumab).
Which of the following statement(s) about amyloidosis is/are true?
What proportion of patients with ATTR amyloidosis also have a serum monoclonal protein?
Which of the following is NOT currently among the investigational therapies for multiple myeloma?